The global market for Axial Spondyloarthritis Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Axial Spondyloarthritis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Axial Spondyloarthritis Drugs.

The Axial Spondyloarthritis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Axial Spondyloarthritis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Axial Spondyloarthritis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Axial Spondyloarthritis Drugs Market Report

Report Metric	Details
Report Name	Axial Spondyloarthritis Drugs Market
CAGR	5%
Segment by Type	Certolizumab Pegol Etanercept Biosimilar Ixekizumab Secukinumab Others
Segment by Application	Clinic Hospital Home Care
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	AstraZeneca Plc, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Panacea Biotec Ltd, Sandoz International GmbH, Sun Pharma Advanced Research Company Ltd, UCB SA
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Axial Spondyloarthritis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Axial Spondyloarthritis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Axial Spondyloarthritis Drugs Market report?

Ans: The main players in the Axial Spondyloarthritis Drugs Market are AstraZeneca Plc, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Panacea Biotec Ltd, Sandoz International GmbH, Sun Pharma Advanced Research Company Ltd, UCB SA

What are the Application segmentation covered in the Axial Spondyloarthritis Drugs Market report?

Ans: The Applications covered in the Axial Spondyloarthritis Drugs Market report are Clinic, Hospital, Home Care

What are the Type segmentation covered in the Axial Spondyloarthritis Drugs Market report?

Ans: The Types covered in the Axial Spondyloarthritis Drugs Market report are Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, Secukinumab, Others

1 Axial Spondyloarthritis Drugs Market Overview

1.1 Product Definition

1.2 Axial Spondyloarthritis Drugs by Type

1.2.1 Global Axial Spondyloarthritis Drugs Market Value Comparison by Type (2024 VS 2031)

1.2.2 Certolizumab Pegol

1.2.3 Etanercept Biosimilar

1.2.4 Ixekizumab

1.2.5 Secukinumab

1.2.6 Others

1.3 Axial Spondyloarthritis Drugs by Application

1.3.1 Global Axial Spondyloarthritis Drugs Market Value by Application (2024 VS 2031)

1.3.2 Clinic

1.3.3 Hospital

1.3.4 Home Care

1.4 Global Axial Spondyloarthritis Drugs Market Size Estimates and Forecasts

1.4.1 Global Axial Spondyloarthritis Drugs Revenue 2020-2031

1.4.2 Global Axial Spondyloarthritis Drugs Sales 2020-2031

1.4.3 Global Axial Spondyloarthritis Drugs Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Axial Spondyloarthritis Drugs Market Competition by Manufacturers

2.1 Global Axial Spondyloarthritis Drugs Sales Market Share by Manufacturers (2020-2025)

2.2 Global Axial Spondyloarthritis Drugs Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Axial Spondyloarthritis Drugs Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Axial Spondyloarthritis Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Axial Spondyloarthritis Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Axial Spondyloarthritis Drugs, Product Type & Application

2.7 Global Key Manufacturers of Axial Spondyloarthritis Drugs, Date of Enter into This Industry

2.8 Global Axial Spondyloarthritis Drugs Market Competitive Situation and Trends

2.8.1 Global Axial Spondyloarthritis Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Axial Spondyloarthritis Drugs Players Market Share by Revenue

2.8.3 Global Axial Spondyloarthritis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Axial Spondyloarthritis Drugs Market Scenario by Region

3.1 Global Axial Spondyloarthritis Drugs Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Axial Spondyloarthritis Drugs Sales by Region: 2020-2031

3.2.1 Global Axial Spondyloarthritis Drugs Sales by Region: 2020-2025

3.2.2 Global Axial Spondyloarthritis Drugs Sales by Region: 2026-2031

3.3 Global Axial Spondyloarthritis Drugs Revenue by Region: 2020-2031

3.3.1 Global Axial Spondyloarthritis Drugs Revenue by Region: 2020-2025

3.3.2 Global Axial Spondyloarthritis Drugs Revenue by Region: 2026-2031

3.4 North America Axial Spondyloarthritis Drugs Market Facts & Figures by Country

3.4.1 North America Axial Spondyloarthritis Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Axial Spondyloarthritis Drugs Sales by Country (2020-2031)

3.4.3 North America Axial Spondyloarthritis Drugs Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Axial Spondyloarthritis Drugs Market Facts & Figures by Country

3.5.1 Europe Axial Spondyloarthritis Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Axial Spondyloarthritis Drugs Sales by Country (2020-2031)

3.5.3 Europe Axial Spondyloarthritis Drugs Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Axial Spondyloarthritis Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Axial Spondyloarthritis Drugs Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Axial Spondyloarthritis Drugs Sales by Region (2020-2031)

3.6.3 Asia Pacific Axial Spondyloarthritis Drugs Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Axial Spondyloarthritis Drugs Market Facts & Figures by Country

3.7.1 Latin America Axial Spondyloarthritis Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Axial Spondyloarthritis Drugs Sales by Country (2020-2031)

3.7.3 Latin America Axial Spondyloarthritis Drugs Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Axial Spondyloarthritis Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Axial Spondyloarthritis Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country (2020-2031)

3.8.3 Middle East and Africa Axial Spondyloarthritis Drugs Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Axial Spondyloarthritis Drugs Sales by Type (2020-2031)

4.1.1 Global Axial Spondyloarthritis Drugs Sales by Type (2020-2025)

4.1.2 Global Axial Spondyloarthritis Drugs Sales by Type (2026-2031)

4.1.3 Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2020-2031)

4.2 Global Axial Spondyloarthritis Drugs Revenue by Type (2020-2031)

4.2.1 Global Axial Spondyloarthritis Drugs Revenue by Type (2020-2025)

4.2.2 Global Axial Spondyloarthritis Drugs Revenue by Type (2026-2031)

4.2.3 Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2020-2031)

4.3 Global Axial Spondyloarthritis Drugs Price by Type (2020-2031)

5 Segment by Application

5.1 Global Axial Spondyloarthritis Drugs Sales by Application (2020-2031)

5.1.1 Global Axial Spondyloarthritis Drugs Sales by Application (2020-2025)

5.1.2 Global Axial Spondyloarthritis Drugs Sales by Application (2026-2031)

5.1.3 Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2020-2031)

5.2 Global Axial Spondyloarthritis Drugs Revenue by Application (2020-2031)

5.2.1 Global Axial Spondyloarthritis Drugs Revenue by Application (2020-2025)

5.2.2 Global Axial Spondyloarthritis Drugs Revenue by Application (2026-2031)

5.2.3 Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2020-2031)

5.3 Global Axial Spondyloarthritis Drugs Price by Application (2020-2031)

6 Key Companies Profiled

6.1 AstraZeneca Plc

6.1.1 AstraZeneca Plc Company Information

6.1.2 AstraZeneca Plc Description and Business Overview

6.1.3 AstraZeneca Plc Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2020-2025)

6.1.4 AstraZeneca Plc Axial Spondyloarthritis Drugs Product Portfolio

6.1.5 AstraZeneca Plc Recent Developments/Updates

6.2 Eli Lilly and Company

6.2.1 Eli Lilly and Company Company Information

6.2.2 Eli Lilly and Company Description and Business Overview

6.2.3 Eli Lilly and Company Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Eli Lilly and Company Axial Spondyloarthritis Drugs Product Portfolio

6.2.5 Eli Lilly and Company Recent Developments/Updates

6.3 Johnson & Johnson

6.3.1 Johnson & Johnson Company Information

6.3.2 Johnson & Johnson Description and Business Overview

6.3.3 Johnson & Johnson Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Johnson & Johnson Axial Spondyloarthritis Drugs Product Portfolio

6.3.5 Johnson & Johnson Recent Developments/Updates

6.4 Novartis AG

6.4.1 Novartis AG Company Information

6.4.2 Novartis AG Description and Business Overview

6.4.3 Novartis AG Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Novartis AG Axial Spondyloarthritis Drugs Product Portfolio

6.4.5 Novartis AG Recent Developments/Updates

6.5 Panacea Biotec Ltd

6.5.1 Panacea Biotec Ltd Company Information

6.5.2 Panacea Biotec Ltd Description and Business Overview

6.5.3 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Product Portfolio

6.5.5 Panacea Biotec Ltd Recent Developments/Updates

6.6 Sandoz International GmbH

6.6.1 Sandoz International GmbH Company Information

6.6.2 Sandoz International GmbH Description and Business Overview

6.6.3 Sandoz International GmbH Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Sandoz International GmbH Axial Spondyloarthritis Drugs Product Portfolio

6.6.5 Sandoz International GmbH Recent Developments/Updates

6.7 Sun Pharma Advanced Research Company Ltd

6.7.1 Sun Pharma Advanced Research Company Ltd Company Information

6.7.2 Sun Pharma Advanced Research Company Ltd Description and Business Overview

6.7.3 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Product Portfolio

6.7.5 Sun Pharma Advanced Research Company Ltd Recent Developments/Updates

6.8 UCB SA

6.8.1 UCB SA Company Information

6.8.2 UCB SA Description and Business Overview

6.8.3 UCB SA Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2020-2025)

6.8.4 UCB SA Axial Spondyloarthritis Drugs Product Portfolio

6.8.5 UCB SA Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Axial Spondyloarthritis Drugs Industry Chain Analysis

7.2 Axial Spondyloarthritis Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Axial Spondyloarthritis Drugs Production Mode & Process Analysis

7.4 Axial Spondyloarthritis Drugs Sales and Marketing

7.4.1 Axial Spondyloarthritis Drugs Sales Channels

7.4.2 Axial Spondyloarthritis Drugs Distributors

7.5 Axial Spondyloarthritis Drugs Customer Analysis

8 Axial Spondyloarthritis Drugs Market Dynamics

8.1 Axial Spondyloarthritis Drugs Industry Trends

8.2 Axial Spondyloarthritis Drugs Market Drivers

8.3 Axial Spondyloarthritis Drugs Market Challenges

8.4 Axial Spondyloarthritis Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Novartis

Panacea Biotec Ltd

Sandoz International Gmbh

Sun Pharma Advanced Research Company Ltd

UCB SA

Company

List of Tables

Table 1. Global Axial Spondyloarthritis Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Axial Spondyloarthritis Drugs Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Axial Spondyloarthritis Drugs Market Competitive Situation by Manufacturers in 2024

Table 4. Global Axial Spondyloarthritis Drugs Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Axial Spondyloarthritis Drugs Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Axial Spondyloarthritis Drugs Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Axial Spondyloarthritis Drugs Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Axial Spondyloarthritis Drugs Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Axial Spondyloarthritis Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Axial Spondyloarthritis Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Axial Spondyloarthritis Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Axial Spondyloarthritis Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Axial Spondyloarthritis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Axial Spondyloarthritis Drugs as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Axial Spondyloarthritis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Axial Spondyloarthritis Drugs Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Axial Spondyloarthritis Drugs Sales Market Share by Region (2020-2025)

Table 19. Global Axial Spondyloarthritis Drugs Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Axial Spondyloarthritis Drugs Sales Market Share by Region (2026-2031)

Table 21. Global Axial Spondyloarthritis Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region (2020-2025)

Table 23. Global Axial Spondyloarthritis Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region (2026-2031)

Table 25. North America Axial Spondyloarthritis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Axial Spondyloarthritis Drugs Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Axial Spondyloarthritis Drugs Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Axial Spondyloarthritis Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Axial Spondyloarthritis Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Axial Spondyloarthritis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Axial Spondyloarthritis Drugs Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Axial Spondyloarthritis Drugs Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Axial Spondyloarthritis Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Axial Spondyloarthritis Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Axial Spondyloarthritis Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Axial Spondyloarthritis Drugs Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Axial Spondyloarthritis Drugs Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Axial Spondyloarthritis Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Axial Spondyloarthritis Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Axial Spondyloarthritis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Axial Spondyloarthritis Drugs Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Axial Spondyloarthritis Drugs Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Axial Spondyloarthritis Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Axial Spondyloarthritis Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Axial Spondyloarthritis Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Axial Spondyloarthritis Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Axial Spondyloarthritis Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Axial Spondyloarthritis Drugs Sales (K Pcs) by Type (2020-2025)

Table 51. Global Axial Spondyloarthritis Drugs Sales (K Pcs) by Type (2026-2031)

Table 52. Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2020-2025)

Table 53. Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2026-2031)

Table 54. Global Axial Spondyloarthritis Drugs Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Axial Spondyloarthritis Drugs Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2020-2025)

Table 57. Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2026-2031)

Table 58. Global Axial Spondyloarthritis Drugs Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Axial Spondyloarthritis Drugs Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Axial Spondyloarthritis Drugs Sales (K Pcs) by Application (2020-2025)

Table 61. Global Axial Spondyloarthritis Drugs Sales (K Pcs) by Application (2026-2031)

Table 62. Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2020-2025)

Table 63. Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2026-2031)

Table 64. Global Axial Spondyloarthritis Drugs Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Axial Spondyloarthritis Drugs Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2020-2025)

Table 67. Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2026-2031)

Table 68. Global Axial Spondyloarthritis Drugs Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Axial Spondyloarthritis Drugs Price (USD/Pcs) by Application (2026-2031)

Table 70. AstraZeneca Plc Company Information

Table 71. AstraZeneca Plc Description and Business Overview

Table 72. AstraZeneca Plc Axial Spondyloarthritis Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. AstraZeneca Plc Axial Spondyloarthritis Drugs Product

Table 74. AstraZeneca Plc Recent Developments/Updates

Table 75. Eli Lilly and Company Company Information

Table 76. Eli Lilly and Company Description and Business Overview

Table 77. Eli Lilly and Company Axial Spondyloarthritis Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Eli Lilly and Company Axial Spondyloarthritis Drugs Product

Table 79. Eli Lilly and Company Recent Developments/Updates

Table 80. Johnson & Johnson Company Information

Table 81. Johnson & Johnson Description and Business Overview

Table 82. Johnson & Johnson Axial Spondyloarthritis Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. Johnson & Johnson Axial Spondyloarthritis Drugs Product

Table 84. Johnson & Johnson Recent Developments/Updates

Table 85. Novartis AG Company Information

Table 86. Novartis AG Description and Business Overview

Table 87. Novartis AG Axial Spondyloarthritis Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. Novartis AG Axial Spondyloarthritis Drugs Product

Table 89. Novartis AG Recent Developments/Updates

Table 90. Panacea Biotec Ltd Company Information

Table 91. Panacea Biotec Ltd Description and Business Overview

Table 92. Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Panacea Biotec Ltd Axial Spondyloarthritis Drugs Product

Table 94. Panacea Biotec Ltd Recent Developments/Updates

Table 95. Sandoz International GmbH Company Information

Table 96. Sandoz International GmbH Description and Business Overview

Table 97. Sandoz International GmbH Axial Spondyloarthritis Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. Sandoz International GmbH Axial Spondyloarthritis Drugs Product

Table 99. Sandoz International GmbH Recent Developments/Updates

Table 100. Sun Pharma Advanced Research Company Ltd Company Information

Table 101. Sun Pharma Advanced Research Company Ltd Description and Business Overview

Table 102. Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Product

Table 104. Sun Pharma Advanced Research Company Ltd Recent Developments/Updates

Table 105. UCB SA Company Information

Table 106. UCB SA Description and Business Overview

Table 107. UCB SA Axial Spondyloarthritis Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. UCB SA Axial Spondyloarthritis Drugs Product

Table 109. UCB SA Recent Developments/Updates

Table 110. Key Raw Materials Lists

Table 111. Raw Materials Key Suppliers Lists

Table 112. Axial Spondyloarthritis Drugs Distributors List

Table 113. Axial Spondyloarthritis Drugs Customers List

Table 114. Axial Spondyloarthritis Drugs Market Trends

Table 115. Axial Spondyloarthritis Drugs Market Drivers

Table 116. Axial Spondyloarthritis Drugs Market Challenges

Table 117. Axial Spondyloarthritis Drugs Market Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Product Picture of Axial Spondyloarthritis Drugs

Figure 2. Global Axial Spondyloarthritis Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Axial Spondyloarthritis Drugs Market Share by Type: 2024 & 2031

Figure 4. Certolizumab Pegol Product Picture

Figure 5. Etanercept Biosimilar Product Picture

Figure 6. Ixekizumab Product Picture

Figure 7. Secukinumab Product Picture

Figure 8. Others Product Picture

Figure 9. Global Axial Spondyloarthritis Drugs Market Value by Application (2020-2031) & (US$ Million)

Figure 10. Global Axial Spondyloarthritis Drugs Market Share by Application: 2024 & 2031

Figure 11. Clinic

Figure 12. Hospital

Figure 13. Home Care

Figure 14. Global Axial Spondyloarthritis Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Axial Spondyloarthritis Drugs Market Size (2020-2031) & (US$ Million)

Figure 16. Global Axial Spondyloarthritis Drugs Sales (2020-2031) & (K Pcs)

Figure 17. Global Axial Spondyloarthritis Drugs Average Price (USD/Pcs) & (2020-2031)

Figure 18. Axial Spondyloarthritis Drugs Report Years Considered

Figure 19. Axial Spondyloarthritis Drugs Sales Share by Manufacturers in 2024

Figure 20. Global Axial Spondyloarthritis Drugs Revenue Share by Manufacturers in 2024

Figure 21. Global 5 and 10 Largest Axial Spondyloarthritis Drugs Players: Market Share by Revenue in Axial Spondyloarthritis Drugs in 2024

Figure 22. Axial Spondyloarthritis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 23. Global Axial Spondyloarthritis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 24. North America Axial Spondyloarthritis Drugs Sales Market Share by Country (2020-2031)

Figure 25. North America Axial Spondyloarthritis Drugs Revenue Market Share by Country (2020-2031)

Figure 26. U.S. Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Canada Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Europe Axial Spondyloarthritis Drugs Sales Market Share by Country (2020-2031)

Figure 29. Europe Axial Spondyloarthritis Drugs Revenue Market Share by Country (2020-2031)

Figure 30. Germany Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. France Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. U.K. Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Italy Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Russia Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Asia Pacific Axial Spondyloarthritis Drugs Sales Market Share by Region (2020-2031)

Figure 36. Asia Pacific Axial Spondyloarthritis Drugs Revenue Market Share by Region (2020-2031)

Figure 37. China Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Japan Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. South Korea Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. India Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Australia Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Taiwan Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Indonesia Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Thailand Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Malaysia Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Philippines Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Latin America Axial Spondyloarthritis Drugs Sales Market Share by Country (2020-2031)

Figure 48. Latin America Axial Spondyloarthritis Drugs Revenue Market Share by Country (2020-2031)

Figure 49. Mexico Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Brazil Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Argentina Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Middle East and Africa Axial Spondyloarthritis Drugs Sales Market Share by Country (2020-2031)

Figure 53. Middle East and Africa Axial Spondyloarthritis Drugs Revenue Market Share by Country (2020-2031)

Figure 54. Turkey Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. UAE Axial Spondyloarthritis Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Global Sales Market Share of Axial Spondyloarthritis Drugs by Type (2020-2031)

Figure 58. Global Revenue Market Share of Axial Spondyloarthritis Drugs by Type (2020-2031)

Figure 59. Global Axial Spondyloarthritis Drugs Price (USD/Pcs) by Type (2020-2031)

Figure 60. Global Sales Market Share of Axial Spondyloarthritis Drugs by Application (2020-2031)

Figure 61. Global Revenue Market Share of Axial Spondyloarthritis Drugs by Application (2020-2031)

Figure 62. Global Axial Spondyloarthritis Drugs Price (USD/Pcs) by Application (2020-2031)

Figure 63. Axial Spondyloarthritis Drugs Value Chain

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-14O17385

Wed Nov 05 00:00:00 UTC 2025

Add to Cart

Global Gout Patches Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-38Z16246

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Rheumatoid Arthritis Devices Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-23A7794

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septic Arthritis Treatment Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9R6120

Tue Sep 16 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Axial Spondyloarthritis Drugs Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-12X494

Global Axial Spondyloarthritis Drugs Market Research Report 2025

FEATURED COMPANIES

Axial Spondyloarthritis Drugs Market Size

Axial Spondyloarthritis Drugs Market

Report Scope

Scope of Axial Spondyloarthritis Drugs Market Report

Core Chapters

FAQ for this report

Who are the main players in the Axial Spondyloarthritis Drugs Market report?

What are the Application segmentation covered in the Axial Spondyloarthritis Drugs Market report?

What are the Type segmentation covered in the Axial Spondyloarthritis Drugs Market report?

FEATURED COMPANIES

RELATED REPORTS